STOCK TITAN
  1. Home
  2. News
  3. AMRX

Amneal Pharmaceuticals Inc - AMRX STOCK NEWS

Welcome to our dedicated news page for Amneal Pharmaceuticals (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amneal Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amneal Pharmaceuticals's position in the market.

News
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) will release its Q4 and full year 2023 financial results on March 1, 2024. A conference call and webcast will be held at 8:30 a.m. ET. The financial results and webcast will be accessible through the Investor Relations section of the Company's website. Participants can register for the conference call and receive dial-in details. A replay of the call will be available for seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences earnings
-
News
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) has received approval and launched fluorometholone ophthalmic suspension, USP, 0.1%, with 180-day competitive generic therapy exclusivity from the FDA. The product is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. The company aims to drive continued growth with the launch of this high-value product in the less crowded and durable ophthalmic category. Adverse effects include short-term inflammatory eye reactions and long-term use effects such as elevation of intraocular pressure and possible development of glaucoma, optic nerve damage, cataract formation, vision problems, and delayed eye wound healing. The U.S. annual sales for FML for the 12 months ended November 2023 were approximately $62 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
News
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) has announced the launch of 39 new retail and injectable medicines in 2023, compared to 26 in 2022. In the fourth quarter of 2023, 13 new products were launched, including 5 injectables. These launches are expected to drive higher injectable revenues in the future, with key new retail products such as spironolactone suspension and icosapent capsules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
earnings
News
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. Chirag Patel and Tasos Konidaris to present on January 10th. Webcast accessible on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
conferences
-
News
Amneal Announces Move to Nasdaq
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will transfer its stock exchange listing to the Nasdaq Stock Market on December 27, 2023. The company will continue to trade under the symbol 'AMRX' and will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and BIAL - Portela & Ca., S.A. announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023. ONGENTYS® is a proprietary once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor), approved by the U.S. Food and Drug Administration in 2020 as an add-on treatment to carbidopa/levodopa (CD/LD) in patients with Parkinson’s disease experiencing “Off” episodes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
News
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) partners with Strides Pharma Science Limited to commercialize Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product, in-licensed from Strides, will be launched in the fourth quarter of 2023. Icosapent ethyl is indicated to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Amneal plans to launch over 40 new products in 2023, including Icosapent ethyl, as part of their portfolio expansion strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.12%
Tags
none
-
News
Amneal Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) reported a net revenue of $620 million, GAAP net income of $10 million, and diluted EPS of $0.06 for Q3 2023. Adjusted net income was $60 million, Adjusted EBITDA was $154 million, and Adjusted Diluted EPS was $0.19. The company affirmed its 2023 full-year guidance, projecting net revenue of $2.37 billion to $2.42 billion, adjusted EBITDA of $540 million to $550 million, and adjusted diluted EPS of $0.51 to $0.58.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
earnings
-
News
Amneal to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will participate in investor conferences, including Jefferies 14th Annual Global Healthcare Conference on November 14, 2023, in London, UK, and Piper Sandler 35th Annual Healthcare Conference on November 28, 2023, in New York, New York. The presentations will be available via live webcast on the company's Investor Relations section of the website, with a replay available for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences
News
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
Rhea-AI Summary
Amneal Pharmaceuticals raises financial guidance for 2023 after strong Q3 performance. Net revenue expected to increase by 13% compared to Q3 2022. Adjusted EBITDA to increase by 21%. Net leverage decreased to 4.6x as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.05%
Tags
earnings
Stock AMRX logo
Amneal Pharmaceuticals Inc

Nasdaq:AMRX

AMRX Rankings

#1941 Ranked by Market Cap
#238 Ranked by Stock Gains
N/A Ranked by Dividends

AMRX Stock Data

1.68B
123.43M
59.78%
29.02%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bridgewater

About AMRX

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.